Jorge A. Garcia, MD, FACP, chairperson of the OncologicDrugs Advisory Committee (ODAC) for the US Food & Drug Administration,shared insight on the recent ODAC meeting where members determined thatolaparib plus abiraterone as an upfront treatment for mCRPC should berestricted to patients with BRCA mutations. Dr. Garcia is a medical oncologistat the University Hospitals Seidman Cancer Center and is the center’s George& Edith Richman Distinguished Scientist Chair, as well as Chief of theirSolid Tumor Oncology division.